Do different anthracycline treatment regimens, cardiac protective agents, or liposomal formulations prevent cardiotoxicity in patients with cancer?
Current evidence from RCTs is insufficient to recommend specific anthracycline regimens, cardioprotective agents, or liposomal formulations to prevent cardiotoxicity in cancer patients.
Evidence is not sufficiently robust to support clear evidence-based recommendations on different anthracycline treatment regimens, or for routine use of cardiac protective agents or liposomal formulations. There is a need to improve cardiac monitoring in oncology trials.
Smith et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: